Loading stock data…
$1.77+0.01 (+0.69%)
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.
Pulmonx Corporation in the Healthcare sector is trading at $1.77 with a market capitalization of $95M. Wall Street consensus targets $3.40 (5 analysts), implying a +91.9% move over the next 12 months. The stock is currently 39% below its 52-week high of $2.89, remaining 6.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.76M↑ | $20.59M↓ | $22.60M↑ | $21.50M↓ | $23.86M |
| Gross Profit | $17.74M↑ | $16.04M↓ | $17.54M↑ | $16.05M↓ | $17.20M |
| Operating Income | -$9.06M↑ | -$12.96M↓ | -$9.90M↑ | -$14.39M↑ | -$14.80M |
| Net Income | -$10.08M↑ | -$13.65M↓ | -$10.43M↑ | -$13.96M↑ | -$15.17M |
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pul...